Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:HIBADH-ST7

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: HIBADH-ST7
	FusionPDB ID: 36295
	FusionGDB2.0 ID: 36295
		Hgene	Tgene
	Gene symbol	HIBADH	ST7
	Gene ID	11112	93655
	Gene name	3-hydroxyisobutyrate dehydrogenase	ST7 overlapping transcript 3
	Synonyms	NS5ATP1	NCRNA00026\|ST7\|ST7OT3
	Cytomap	7p15.2	7q31.2
	Type of gene	protein-coding	ncRNA
	Description	3-hydroxyisobutyrate dehydrogenase, mitochondrial3'-hydroxyisobutyrate dehydrogenaseepididymis secretory sperm binding protein	ST7 overlapping transcript 3 (non-coding RNA)ST7 overlapping transcript 3 (non-protein coding)suppression of tumorigenicity 7
	Modification date	20200313	20200313
	UniProtAcc	P31937 Main function of 5'-partner protein:	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000265395,	ENST00000393443, ENST00000393444, ENST00000393447, ENST00000465133, ENST00000487459, ENST00000265437, ENST00000323984, ENST00000393446, ENST00000393449, ENST00000393451, ENST00000422922, ENST00000432298,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	5 X 4 X 5=100	13 X 10 X 8=1040
	# samples	7	14
	** MAII score	log2(7/100*10)=-0.514573172829758 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(14/1040*10)=-2.89308479608349 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: HIBADH [Title/Abstract] AND ST7 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: HIBADH [Title/Abstract] AND ST7 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	HIBADH(27702316)-ST7(116759614), # samples:1
Anticipated loss of major functional domain due to fusion event.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	HIBADH	GO:0006574	valine catabolic process	16466957

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:27702316/chr7:116759614)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across HIBADH (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ST7 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000265395	HIBADH	chr7	27702316	-	ENST00000393446	ST7	chr7	116759614	+	1875	298	13	1635	540
ENST00000265395	HIBADH	chr7	27702316	-	ENST00000265437	ST7	chr7	116759614	+	2749	298	13	1821	602
ENST00000265395	HIBADH	chr7	27702316	-	ENST00000393451	ST7	chr7	116759614	+	1975	298	13	1728	571
ENST00000265395	HIBADH	chr7	27702316	-	ENST00000393449	ST7	chr7	116759614	+	2029	298	13	1782	589
ENST00000265395	HIBADH	chr7	27702316	-	ENST00000323984	ST7	chr7	116759614	+	2044	298	13	1797	594
ENST00000265395	HIBADH	chr7	27702316	-	ENST00000432298	ST7	chr7	116759614	+	2044	298	13	1797	594
ENST00000265395	HIBADH	chr7	27702316	-	ENST00000422922	ST7	chr7	116759614	+	1975	298	13	1728	571

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000265395	ENST00000393446	HIBADH	chr7	27702316	-	ST7	chr7	116759614	+	0.0017725	0.99822754
ENST00000265395	ENST00000265437	HIBADH	chr7	27702316	-	ST7	chr7	116759614	+	0.002851502	0.99714845
ENST00000265395	ENST00000393451	HIBADH	chr7	27702316	-	ST7	chr7	116759614	+	0.002382575	0.9976174
ENST00000265395	ENST00000393449	HIBADH	chr7	27702316	-	ST7	chr7	116759614	+	0.003311801	0.9966882
ENST00000265395	ENST00000323984	HIBADH	chr7	27702316	-	ST7	chr7	116759614	+	0.003338711	0.9966613
ENST00000265395	ENST00000432298	HIBADH	chr7	27702316	-	ST7	chr7	116759614	+	0.003338711	0.9966613
ENST00000265395	ENST00000422922	HIBADH	chr7	27702316	-	ST7	chr7	116759614	+	0.002382575	0.9976174

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for HIBADH-ST7

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
HIBADH	chr7	27702316	ST7	chr7	116759614	298	95	AGGCGRQPAALQRIFEWWYFRKYGTS

Top

Potential FusionNeoAntigen Information of HIBADH-ST7 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

HIBADH-ST7_27702316_116759614.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B51:01	QPAALQRI	0.994	0.738	6	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B51:02	QPAALQRI	0.968	0.7744	6	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:02	QRIFEWWYF	0.9997	0.7352	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:05	QRIFEWWYF	0.9997	0.9275	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B57:01	AALQRIFEW	0.9997	0.9931	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:04	QRIFEWWYF	0.9996	0.7993	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B58:02	AALQRIFEW	0.9993	0.9821	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B58:01	AALQRIFEW	0.9992	0.9864	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:07	QRIFEWWYF	0.9979	0.6132	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A74:09	RIFEWWYFR	0.9974	0.5873	12	21
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A74:11	RIFEWWYFR	0.9974	0.5873	12	21
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A74:03	RIFEWWYFR	0.9974	0.5873	12	21
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:17	AALQRIFEW	0.9972	0.9689	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A31:08	AALQRIFEW	0.995	0.7337	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B57:03	AALQRIFEW	0.9927	0.9963	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A31:02	RIFEWWYFR	0.9897	0.5776	12	21
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B07:02	QPAALQRIF	0.9893	0.5005	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:16	AALQRIFEW	0.9889	0.9444	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B07:05	QPAALQRIF	0.9873	0.5857	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:01	QPAALQRIF	0.9808	0.8233	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A32:13	AALQRIFEW	0.9805	0.9832	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:08	QPAALQRIF	0.9651	0.8567	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A32:13	ALQRIFEWW	0.965	0.9829	9	18
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B53:01	AALQRIFEW	0.9573	0.77	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:05	QPAALQRIF	0.9535	0.7225	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:03	QPAALQRIF	0.9252	0.8626	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B53:01	QPAALQRIF	0.8929	0.6652	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B48:01	RQPAALQRI	0.8299	0.7077	5	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B13:02	RQPAALQRI	0.5845	0.8974	5	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:04	QPAALQRIF	0.5653	0.9569	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:02	QPAALQRIF	0.5653	0.9569	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B13:01	RQPAALQRI	0.3391	0.9686	5	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B82:01	QPAALQRIF	0.1425	0.7437	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B81:01	QPAALQRIF	0.0657	0.6395	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B52:01	RQPAALQRI	0.0336	0.9686	5	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B57:01	AALQRIFEWW	0.9998	0.9938	8	18
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:01	RQPAALQRIF	0.9997	0.8004	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:07	GRQPAALQRI	0.9995	0.6723	4	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B58:02	AALQRIFEWW	0.9984	0.9872	8	18
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B58:01	AALQRIFEWW	0.9974	0.9892	8	18
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B57:03	AALQRIFEWW	0.9893	0.9972	8	18
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B07:02	RQPAALQRIF	0.8589	0.6875	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:05	GRQPAALQRIF	1	0.5064	4	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:04	GRQPAALQRIF	1	0.7681	4	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:07	GRQPAALQRIF	0.9999	0.6441	4	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B57:01	QPAALQRIFEW	0.9995	0.9905	6	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:02	ALQRIFEWWYF	0.9927	0.6625	9	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B58:01	QPAALQRIFEW	0.9923	0.9832	6	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B53:01	QPAALQRIFEW	0.9695	0.8555	6	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B51:08	QPAALQRI	0.9858	0.6909	6	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:14	QRIFEWWYF	0.9997	0.8727	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:95	QRIFEWWYF	0.999	0.8354	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A31:01	RIFEWWYFR	0.9977	0.536	12	21
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:05	QRIFEWWYF	0.9976	0.9643	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:03	QRIFEWWYF	0.996	0.9339	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:19	QRIFEWWYF	0.9958	0.6957	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:27	QRIFEWWYF	0.9946	0.956	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:46	QRIFEWWYF	0.9938	0.8769	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:67	QRIFEWWYF	0.9916	0.9455	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:80	QRIFEWWYF	0.9916	0.9455	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:10	QRIFEWWYF	0.9903	0.9615	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B07:12	QPAALQRIF	0.8128	0.7111	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B44:08	AALQRIFEW	0.8122	0.7331	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B42:02	QPAALQRIF	0.7986	0.8392	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B42:01	QPAALQRIF	0.7186	0.8327	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B07:04	QPAALQRIF	0.6767	0.5722	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:12	QPAALQRIF	0.5653	0.9569	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B56:04	QPAALQRIF	0.5008	0.6592	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B48:03	RQPAALQRI	0.3998	0.6095	5	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B39:10	QPAALQRIF	0.2562	0.9146	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:07	RQPAALQRIF	0.9989	0.7484	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B07:04	RQPAALQRIF	0.9022	0.7073	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B07:12	RQPAALQRIF	0.8788	0.8158	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:95	GRQPAALQRIF	0.9998	0.7019	4	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:03	GRQPAALQRIF	0.9982	0.5404	4	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B44:06	QPAALQRIFEW	0.9786	0.6787	6	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A32:01	RIFEWWYF	0.9987	0.9756	12	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B51:13	QPAALQRI	0.9941	0.6557	6	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B51:14	QPAALQRI	0.9905	0.7924	6	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B51:29	QPAALQRI	0.9815	0.6	6	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B51:09	QPAALQRI	0.9805	0.7041	6	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B51:21	QPAALQRI	0.963	0.7723	6	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B51:05	QPAALQRI	0.9451	0.5251	6	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B59:01	QPAALQRI	0.7365	0.7165	6	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:08	QRIFEWWYF	0.9997	0.8528	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B57:10	AALQRIFEW	0.9997	0.9931	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:10	QRIFEWWYF	0.9996	0.9032	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:06	QRIFEWWYF	0.9992	0.8244	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:01	QRIFEWWYF	0.9991	0.6975	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B58:06	AALQRIFEW	0.9986	0.9725	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B57:04	AALQRIFEW	0.9984	0.9423	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A74:01	RIFEWWYFR	0.9974	0.5873	12	21
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:09	QRIFEWWYF	0.9966	0.9287	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A32:01	AALQRIFEW	0.9962	0.9917	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:02	QRIFEWWYF	0.9916	0.9455	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B07:09	QPAALQRIF	0.9899	0.5344	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B07:22	QPAALQRIF	0.9893	0.5005	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A32:01	ALQRIFEWW	0.9839	0.9911	9	18
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:13	AALQRIFEW	0.9815	0.9268	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:77	QPAALQRIF	0.9808	0.8233	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:23	QPAALQRIF	0.9793	0.8641	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B57:02	AALQRIFEW	0.9784	0.9813	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:20	QPAALQRIF	0.9762	0.8567	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:17	QPAALQRIF	0.9561	0.7883	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:30	QPAALQRIF	0.9561	0.7883	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:11	QPAALQRIF	0.9504	0.8471	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:24	QPAALQRIF	0.9418	0.8223	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:22	QRIFEWWYF	0.9238	0.8378	11	20
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:73	RQPAALQRI	0.9214	0.9416	5	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B53:02	AALQRIFEW	0.9183	0.8583	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:13	QPAALQRIF	0.8562	0.9321	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B53:02	QPAALQRIF	0.8439	0.6795	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:22	QPAALQRIF	0.7128	0.5767	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B55:04	QPAALQRIF	0.5834	0.6485	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:09	QPAALQRIF	0.5653	0.9569	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:24	AALQRIFEW	0.5576	0.981	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B56:02	QPAALQRIF	0.5008	0.6592	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B51:06	QPAALQRIF	0.4632	0.6293	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B40:12	RQPAALQRI	0.3998	0.6095	5	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B67:01	QPAALQRIF	0.2709	0.8907	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B48:05	RQPAALQRI	0.2686	0.5433	5	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C16:04	AALQRIFEW	0.2414	0.9933	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C16:02	AALQRIFEW	0.2266	0.9954	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B18:07	QPAALQRIF	0.2148	0.8425	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B35:43	QPAALQRIF	0.1677	0.8175	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:08	QPAALQRIF	0.166	0.8177	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:11	QPAALQRIF	0.1608	0.8186	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B82:02	QPAALQRIF	0.1425	0.7437	6	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A25:01	AALQRIFEW	0.1201	0.9657	8	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B57:10	AALQRIFEWW	0.9998	0.9938	8	18
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:33	RQPAALQRIF	0.9997	0.8004	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:34	RQPAALQRIF	0.9997	0.8004	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:125	RQPAALQRIF	0.9997	0.8004	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:27	RQPAALQRIF	0.9997	0.8739	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:135	RQPAALQRIF	0.9997	0.804	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:24	RQPAALQRIF	0.9996	0.8834	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:50	RQPAALQRIF	0.9995	0.9041	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:06	GRQPAALQRI	0.9995	0.842	4	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:09	GRQPAALQRI	0.9994	0.6184	4	14
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B57:04	AALQRIFEWW	0.9991	0.9362	8	18
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:68	RQPAALQRIF	0.9985	0.7053	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:53	RQPAALQRIF	0.9985	0.8	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:54	RQPAALQRIF	0.9983	0.7847	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B15:35	RQPAALQRIF	0.997	0.8433	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B57:02	AALQRIFEWW	0.9869	0.9883	8	18
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B07:09	RQPAALQRIF	0.8768	0.7231	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B07:22	RQPAALQRIF	0.8589	0.6875	5	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:10	GRQPAALQRIF	1	0.8107	4	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-C07:01	GRQPAALQRIF	0.9999	0.7057	4	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B27:06	GRQPAALQRIF	0.9999	0.7919	4	15
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B57:10	QPAALQRIFEW	0.9995	0.9905	6	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-B53:02	QPAALQRIFEW	0.9717	0.8544	6	17
HIBADH-ST7	chr7	27702316	chr7	116759614	298	HLA-A32:01	RIFEWWYFRKY	0.9704	0.9243	12	23

Top

Potential FusionNeoAntigen Information of HIBADH-ST7 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of HIBADH-ST7

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
7445	QPAALQRIFEWWYF	HIBADH	ST7	chr7	27702316	chr7	116759614	298

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of HIBADH-ST7

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	7445	QPAALQRIFEWWYF	-7.15543	-7.26883
HLA-B14:02	3BVN	7445	QPAALQRIFEWWYF	-4.77435	-5.80965
HLA-B52:01	3W39	7445	QPAALQRIFEWWYF	-6.80875	-6.92215
HLA-B52:01	3W39	7445	QPAALQRIFEWWYF	-4.20386	-5.23916
HLA-A11:01	4UQ2	7445	QPAALQRIFEWWYF	-7.5194	-8.5547
HLA-A11:01	4UQ2	7445	QPAALQRIFEWWYF	-6.9601	-7.0735
HLA-A24:02	5HGA	7445	QPAALQRIFEWWYF	-7.52403	-7.63743
HLA-A24:02	5HGA	7445	QPAALQRIFEWWYF	-5.82433	-6.85963
HLA-B27:05	6PYJ	7445	QPAALQRIFEWWYF	-3.28285	-4.31815
HLA-B44:05	3DX8	7445	QPAALQRIFEWWYF	-5.91172	-6.94702
HLA-B44:05	3DX8	7445	QPAALQRIFEWWYF	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of HIBADH-ST7

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
HIBADH-ST7	chr7	27702316	chr7	116759614	11	20	QRIFEWWYF	CAGCGGATATTTGAATGGTGGTATTTT
HIBADH-ST7	chr7	27702316	chr7	116759614	12	20	RIFEWWYF	CGGATATTTGAATGGTGGTATTTT
HIBADH-ST7	chr7	27702316	chr7	116759614	12	21	RIFEWWYFR	CGGATATTTGAATGGTGGTATTTTCGC
HIBADH-ST7	chr7	27702316	chr7	116759614	12	23	RIFEWWYFRKY	CGGATATTTGAATGGTGGTATTTTCGCAAATAC
HIBADH-ST7	chr7	27702316	chr7	116759614	4	14	GRQPAALQRI	GGCCGGCAGCCGGCAGCTTTGCAGCGGATA
HIBADH-ST7	chr7	27702316	chr7	116759614	4	15	GRQPAALQRIF	GGCCGGCAGCCGGCAGCTTTGCAGCGGATATTT
HIBADH-ST7	chr7	27702316	chr7	116759614	5	14	RQPAALQRI	CGGCAGCCGGCAGCTTTGCAGCGGATA
HIBADH-ST7	chr7	27702316	chr7	116759614	5	15	RQPAALQRIF	CGGCAGCCGGCAGCTTTGCAGCGGATATTT
HIBADH-ST7	chr7	27702316	chr7	116759614	6	14	QPAALQRI	CAGCCGGCAGCTTTGCAGCGGATA
HIBADH-ST7	chr7	27702316	chr7	116759614	6	15	QPAALQRIF	CAGCCGGCAGCTTTGCAGCGGATATTT
HIBADH-ST7	chr7	27702316	chr7	116759614	6	17	QPAALQRIFEW	CAGCCGGCAGCTTTGCAGCGGATATTTGAATGG
HIBADH-ST7	chr7	27702316	chr7	116759614	8	17	AALQRIFEW	GCAGCTTTGCAGCGGATATTTGAATGG
HIBADH-ST7	chr7	27702316	chr7	116759614	8	18	AALQRIFEWW	GCAGCTTTGCAGCGGATATTTGAATGGTGG
HIBADH-ST7	chr7	27702316	chr7	116759614	9	18	ALQRIFEWW	GCTTTGCAGCGGATATTTGAATGGTGG
HIBADH-ST7	chr7	27702316	chr7	116759614	9	20	ALQRIFEWWYF	GCTTTGCAGCGGATATTTGAATGGTGGTATTTT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of HIBADH-ST7

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
STAD	HIBADH-ST7	chr7	27702316	ENST00000265395	chr7	116759614	ENST00000265437	TCGA-IN-A6RL

Top

Potential target of CAR-T therapy development for HIBADH-ST7

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

ST7

chr7:27702316

chr7:116759614

ENST00000265437

512_532

586.0

Transmembrane

Helical

Tgene

ST7

chr7:27702316

chr7:116759614

ENST00000393443

512_532

500.0

Transmembrane

Helical

Tgene

ST7

chr7:27702316

chr7:116759614

ENST00000393443

62_82

500.0

Transmembrane

Helical

Tgene

ST7

chr7:27702316

chr7:116759614

ENST00000393451

512_532

555.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to HIBADH-ST7

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to HIBADH-ST7

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)